Post-approval Safety Surveillance Study of Golimumab in the Treatment of Rheumatic Disease Using a United States Healthcare Claims Database

BACKGROUND AND OBJECTIVE: Golimumab is a fully human anti-tumor necrosis factor monoclonal antibody approved for the treatment of rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS). This study estimated rates of prespecified outcomes in patients with RA, PsA or AS...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Clin Drug Investig
Egile Nagusiak: Ziyadeh, Najat J., Geldhof, Anja, Noël, Wim, Otero-Lobato, Marijo, Esslinger, Suzan, Chakravarty, Soumya D., Wang, Yiting, Seeger, John D.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Springer International Publishing 2020
Gaiak:
Original Research Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7595963/
https://ncbi.nlm.nih.gov/pubmed/32779120
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40261-020-00959-7
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak